Growth in this market is driven by the rising global incidence of chronic diseases, increasing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot and FluoroSpot assay kits and analyzers. On the other hand, the availability of alternative detection technologies is expected to limit market growth during the forecast period. 

By product type, the ELISpot and FluoroSpot market is segmented into assay kits, analyzers, and ancillary products. The assay kits segment accounted for the largest share in 2018, and this trend is expected to continue during the forecast period. The rising incidence of chronic diseases and technological advancements are driving the growth of this product segment. 

Based on the applications, the ELISpot and FluoroSpot market is segmented into diagnostic and research applications. The diagnostics applications segment is further classified into infectious diseases and transplants. In 2018, the diagnostic segment is expected to account for the larger share of the market. The large share of this segment is attributed to the rising global prevalence of infectious diseases and the increasing use of ELISpot kits for disease diagnosis. 

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124350584 

The ELISpot and FluoroSpot market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). While North America is expected to dominate the market in 2018, Asia Pacific is expected to register the highest CAGR in the market during the forecast period. Growth in APAC is largely driven by the large patient population and high prevalence of chronic diseases in this region. 

Some of the prominent players in the ELISpot Assay Market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK).